Low serum levels of vitamin D in idiopathic inflammatory myopathies

Annals of the Rheumatic Diseases

Volumn 72, Issue 4, 2013, Pages 512-516

  Azali, Payam ^a   Helmers, Sevim Barbasso ^b   Kockum, Ingrid ^b   Olsson, Tomas ^b   Alfredsson, Lars ^b   Charles, Peter J ^c   Aulin, Karin Piehl ^a   Lundberg, Ingrid E ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; AUTOANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; HUMAN; INCLUSION BODY MYOSITIS; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALE; POLYMYOSITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; DERMATOMYOSITIS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; RETROSPECTIVE STUDIES; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84874427940     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201849     Document Type: Article

References (48)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
2. Griggs RC, Askanas V, Di Mauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
3. Reed AM, Ernste F. The inflammatory milieu in idiopathic inflammatory myositis. Curr Rheumatol Rep 2009;11:295-301.
4. Targoff IN. Idiopathic inflammatory myopathy: autoantibody update. Curr Rheumatol Rep 2002;4:434-41.
5. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23. (Pubitemid 32102201)
6. Zampieri S, Ghirardello A, Iaccarino L, et al. Anti-Jo-1 antibodies. Autoimmunity 2005;38:73-8. (Pubitemid 40515006)
7. Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006;66:S39-48. (Pubitemid 43739983)
8. Dalakas MC. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006;2:437-47. (Pubitemid 44137945)
9. Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:891-16.
10. Atlas E, Novak SN, Duray PH, et al. Lyme myositis: muscle invasion by Borrelia burgdorferi. Ann Intern Med 1988;109:245-6.
11. Okada S, Weatherhead E, Targoff IN, et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003;48:2285-93. (Pubitemid 36959210)
12. Wortmann RL. Lipid-lowering agents and myopathy. Curr Opin Rheumatol 2002;14:643-7. (Pubitemid 35191549)
13. Hengstman GJ, Van Venrooij WJ, Vencovsky J, et al. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis 2000;59:141-2. (Pubitemid 30305613)
14. Sontheimer RD. Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Photochem Photobiol 1996;63:583-94. (Pubitemid 126467133)
15. Leff RL, Burgess SH, Miller FW, et al. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum 1991;34:1391-6.
16. *15. Eur J Neurol 2012;19:955-62.
17. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80:1678S-88S.
18. Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006;5:114-17. (Pubitemid 43129539)
19. Cutolo M, Plebani M, Shoenfeld Y, et al. Vitamin D endocrine system and the immune response in rheumatic diseases. Vitam Horm 2011;86:327-51.
20. De Luca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80:1689S-96S.
21. Bhalla AK, Amento EP, Serog B, et al. 1, 25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 1984;133:1748-54. (Pubitemid 14035260)
22. Lemire JM. Immunomodulatory role of 1, 25-dihydroxyvitamin D3. J Cell Biochem 1992;49:26-31.
23. Mattner F, Smiroldo S, Galbiati F, et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1, 25-dihydroxyvitamin D (3). Eur J Immunol 2000;30:498-508. (Pubitemid 30098842)
24. Van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005;97:93-101.
25. Griffin MD, Lutz WH, Phan VA, et al. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000;270:701-8. (Pubitemid 30444768)
26. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1, 25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998;101:252-62. (Pubitemid 28058925)
27. Helming L, Bose J, Ehrchen J, et al. 1alpha, 25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005;106:4351-8. (Pubitemid 41775947)
28. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
29. Hedstrom AK, Sundqvist E, Baarnhielm M, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011;134:653-64.
30. Cantorna MT, Hayes CE, De Luca HF. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996;93:7861-4. (Pubitemid 26277129)
31. Sundqvist E, Baarnhielm M, Alfredsson L, et al. Confirmation of association between multiple sclerosis and CYP27B1. Eur J Hum Genet 2010;18:1349-52.
32. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. Faseb J 2001;15:2579-85. (Pubitemid 33131084)
33. Burd CJ, Kinyamu HK, Miller FW, et al. UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem 2008;283:34976-82.
34. Birmingham D, Hebert L, Song H, et al. Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus 2012;21:855-64.
35. Cutolo M, Otsa K, Laas K, et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol 2006;24:702-4. (Pubitemid 46138805)
36. Cutolo M. Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol 2011;7:500-2.
37. Ritterhouse LL, Crowe SR, Niewold TB, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011;70:1569-74.
38. Mok CC, Birmingham DJ, Ho LY, et al. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus 2012;21:36-42.
39. Eloranta ML, Barbasso Helmers S, Ulfgren AK, et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56:3112-24.
40. Krystufkova O, Vallerskog T, Barbasso Helmers S, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 2009;68:836-43.
41. Niewold TB, Kariuki SN, Morgan GA, et al. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009;60:1815-24.
42. Lindvall B, Bengtsson A, Ernerudh J, et al. Subclinical myositis is common in primary Sjogren's syndrome and is not related to muscle pain. J Rheumatol 2002;29:717-25. (Pubitemid 34303865)
43. Van Etten E, Branisteanu DD, Overbergh L, et al. Combination of a 1, 25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 2003;32:397-404. (Pubitemid 36407540)
44. Lemire JM, Archer DC. 1, 25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-7.
45. Cantorna MT, Hayes CE, De Luca HF. 1, 25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998;128:68-72. (Pubitemid 28087178)
46. Mathieu C, Waer M, Laureys J, et al. Prevention of autoimmune diabetes in NOD mice by 1, 25 dihydroxyvitamin D3. Diabetologia 1994;37:552-8. (Pubitemid 24162425)
47. Fournier C, Gepner P, Sadouk M, et al. In vivo beneficial effects of cyclosporin A and 1, 25-dihydroxyvitamin D3 on the induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 1990;54:53-63. (Pubitemid 20024668)
48. Jagannath VA, Fedorowicz Z, Asokan GV, et al. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev 2010;CD008422.